Takeda’s Fruzaqla (Fruquintinib) Gets FDA Nod for Metastatic Colorectal Cancer

Takeda has announced that the US Food and Drug Administration (FDA) has granted approval for Fruzaqla (fruquintinib) for adults with previously treated metastatic colorectal cancer (mCRC). More specifically, this oral targeted therapy is for adults with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.